Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-424-3 | CAS number: 95-49-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1982
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: well documented and scientifically acceptable - comparable to guideline
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 983
- Report date:
- 1983
Materials and methods
- Principles of method if other than guideline:
- From gestation days (GD) 6 to 19, 25 animals/dose group were transferred daily to exposure chambers and exposed to a an atmosphere of the test material at concentrations of 0, 1, 3, or 9 mg/litre air for 6 hours. All animals were killed on day 20 of pregnancy, dissected and examined for abnormalities and changes in maternal organs. The ovaries and uteri were examined to determine number of corpora lutea, number of distribution of live young, number and distribution of embryonic/foetal deaths, individual foetal weight, gross foetal abnormalities. half of the pups in each litter were preserved for subsequent sectioning to discover visceral abnormalities; the remainder were fixed for skeletal examination.
- GLP compliance:
- yes
Test material
- Reference substance name:
- 2-chlorotoluene
- EC Number:
- 202-424-3
- EC Name:
- 2-chlorotoluene
- Cas Number:
- 95-49-8
- Molecular formula:
- C7H7Cl
- IUPAC Name:
- 1-chloro-2-methylbenzene
1
Test animals
- Species:
- rat
- Strain:
- other: CrL : COBS CD (SD) BR
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River UK Limited, Manston Road, Magate, Kent, UK
- Age at study initiation: mature females
- Weight at study initiation: 166 - 208 g
- Housing: in suspended polypropylene cages with stainless steel mesh floors and tops. Undercage plastic trays were lined with absorbent paper which was inspected and changed daily.
- Diet: Spratt's Laboratory Diet No.l, ad libitum
- Water: tap water , ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 +- 4
- Humidity (%): 60 +- 15
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- inhalation: vapour
- Type of inhalation exposure (if applicable):
- whole body
- Vehicle:
- unchanged (no vehicle)
- Details on exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: test substance was delivered at a controlled rate through a stainless steel metering valve (Nupro Company, 4800 East 345th Street, Willoughby, Ohio 44094, U.S.A.) to an all-glass concentric jet atomiser. The test substance was supplied from a central reservoir constructed from stainless steel which was pressurised to approximately 200 mm Hg using nitrogen from a compressed gas cylinder. Test substance was fed to 3 metering valves (one for each dose group) through stainless steel tubing (i.d. 5 mm). A flexible PVC tube was used to connect the metering valve to the glass atomiser.
Compressed air was delivered to the glass atomiser at 25 litres/min through a flowmeter with needle valve control, to generate an aerosol of 2-chlorotoluene. The atomiser was fitted into the top of a doublesurface glass condenser which was heated by steam generated from an electrically heated water boiler. The aerosol of 2-chlorotoluene was vaporised by contact with the heated glass surfaces of the condenser. The vapour passed into a glass flask before being delivered to the inlet duct of the exposure chamber. In order to minimise the risk of vapour condensing before reaching the chamber, diluent air was fed at 20 litres/min to a side arm of the atomiser and the air was heated as it passed through the condenser.
- Method of holding animals in test chamber: The rats were held during exposure in stainless steel mesh cages placed on supports in the chamber. The cages were subdivided to isolate each rat within an equal sized compartment such that 4 rats were placed in each cage. The rats were positioned on a different tier in the chambers daily.
-Room air was drawn through each chamber by an extract unit, air entering each chamber through a 50 mm i.d. inlet duct fitted with an in-line venturi nozzle used to measure the airflow. The extracted air was diluted and vented through a stack mounted on the roof of the building. The chambers were operated at an internal pressure of 2030 mm H^O below ambient to prevent the escape of test substance into the laboratory. The test vapour was introduced into the chamber inlet duct above the venturi nozzle.
- The target total airflow through each chamber was 250 litres/minute. At this flow rate the calculated 95% chamber equilibration time was 12 minutes.
The rats were held during exposure in stainless steel mesh cages placed on supports in the chamber. The cages were subdivided to isolate each rat within an equal sized compartment such that 4 rats were placed in each cage. The rats were positioned on a different tier in the chambers daily.
TEST ATMOSPHERE
- Brief description of analytical method used: Concentrations of 2-chlorotoluene in the test chambers were measured using a Miran 1 portable infra-red gas analyser fitted with a 20 m variable path-length gas cell (Wilks Scientific Corporation, 140 Water Street, Box 449, South Norwalk, Connecticut, U.S.A.).
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The measured chamber concentrations of 2-chlorotoluene gave values close to the target concentration for all test groups on all days of exposure:
0, 1.1, 3,1; 9.0 mg/l - Details on mating procedure:
- Animals were not mated during the study.
- Duration of treatment / exposure:
- days 6-19 of gestation
- Frequency of treatment:
- 6 h/d
- Duration of test:
- days 6-19 of gestation
Doses / concentrationsopen allclose all
- Dose / conc.:
- 9 mg/L air (nominal)
- Dose / conc.:
- 3 mg/L air (nominal)
- Dose / conc.:
- 1 mg/L air (nominal)
- Dose / conc.:
- 0 mg/L air (nominal)
- No. of animals per sex per dose:
- 25
- Control animals:
- yes, concurrent no treatment
- Details on study design:
- Sex: female
Duration of test: on day 20 of gestation the dams were killed
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: daily
BODY WEIGHT: Yes
- Time schedule for examinations: on day 1, 3, 6, 10, 14, 17 and 20
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 20
- Organs examined: Not provided in the study report. However, based on findings at least kidney and lungs were examined
FOOD CONSUMPTION: Yes
- Food consumption was measured daily for each cage of animals
WATER CONSUMPTION: Yes
- Water consumption was measured daily for each cage of animals
- Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: No
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes - Blood sampling:
- No
- Fetal examinations:
- - External examinations: Yes:
- Soft tissue examinations: Yes, half per litter
- Skeletal examinations: Yes, half per litter
The following parameters were examined for foetuses:
- Number of distribution of live young
- Number of distribution of embryonic/foetal death
- individual foetal weight
- sex ratio - Statistics:
- Statistical analyses were performed routinely on litter data and incidences of skeletal variants, using the litter as the basic sample unit and non-parametric methods (Jonckheere, Kruskal-Wallise) as these values rarely follow a normal distribution.
- Indices:
- Pregnancy rate was determined.
In assessing litter data pre-implantation loss was calculated for each litter as a percentage from the formula:
((Number of corpora lutea - Number of implantations)/Number of corpora lutea) x 100;
Post implantation loss was similarly calculated from the formula:
((Number of implantations - Number of live young)/Number of implantations) x 100
For all values expressed as a percentage or ratio, values were first calculated within the litter and the group values derived as a mean of individual litter percentages.
Calculation of separate mean A values (includes all surviving pregnant animals) and mean B values (includes all surviving dams with viable young), was not applicable in this study as there were no total litter losses. - Historical control data:
- Not provided
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- At 9 mg/l all animals showed slight to moderate ataxia during exposure and occasional animals showed lachrymation and/or salivation.
At 3 mg/l all animals showed slight ataxia during exposure.
There were no signs at 1 mg/l that were observed specifically during the exposure periods.
General signs included brown fur staining among all animals at 9 mg/l and an increased incidence of animals showing some fur loss at 1 and 3 mg/l. - Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- At 9 mg/l mean bodyweight gain was markedly reduced.
Mean bodyweight gain at 3 mg/l was slightly reduced from the start of treatment through to Day 10 of pregnancy and parity with control animals was not subsequently regained.
Mean bodyweight gain at 1 mg/l was essentially similar to that of control animals. - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- At 9 mg/l mean food consumption was significantly reduced from the start of treatment through to termination.
Mean values for food consumption at 3 mg/l were consistently slightly lower than control values although the differences were not statistically significant (P>0.05).
Mean food consumption 1 mg/l was essentially unaffected by treatment. - Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- effects observed, treatment-related
- Description (incidence and severity):
- Mean water consumption was significantly increased at 3 and 9 mg/l from the start of treatment, with markedly increased values occurring at 9 mg/l.
At 1 mg/l mean water consumption was unaffected by treatment. - Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Endocrine findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Occasional macroscopic visceral changes observed at terminal autopsy appeared unrelated to treatment.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
Maternal developmental toxicity
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Slight intergroup differences among mean values for litter size and pre- and post implantation losses were neither statistically significant (P>0.05) nor dosage-related.
- Total litter losses by resorption:
- no effects observed
- Description (incidence and severity):
- There were no instances of total resorption.
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- not examined
- Changes in number of pregnant:
- no effects observed
Effect levels (maternal animals)
- Dose descriptor:
- NOAEC
- Effect level:
- 1.1 mg/L air (analytical)
- Basis for effect level:
- other: maternal toxicity
Results (fetuses)
- Fetal body weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- At 9 mg/l litter and mean foetal weight were significantly reduced (P<0.01 and P<0.001, respectively).
Litter and mean foetal weights at 1 and 3 mg/l appeared essentially unaffected by treatment. Marginally lower values for mean foetal weight relative to the control group probably reflected the slightly higher mean litter size, and hence greater intra-litter competition, that occurred in both groups. - Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- effects observed, treatment-related
- Description (incidence and severity):
- see above "Fetal body weight changes"
- Anogenital distance of all rodent fetuses:
- not examined
- Changes in postnatal survival:
- not examined
- External malformations:
- effects observed, treatment-related
- Description (incidence and severity):
- At 9 mg/l there was an increased incidence of malformed foetuses mainly due to the occurrence of six foetuses, distributed among four litters, showing brachydactyly. One of these affected pups also showed brachymelia of one hind limb. The three other malformations at 9 mg/l involved single foetuses showing respectively microphthalmia, anophthalmia and cardiac ventricular septal defect. The brachydactyly malformation involved the loss of the claw and terminal phalanx of one or more digits. All six foetuses showed a single affected fore or hind paw. For five of the six foetuses the brachydactyly was associated with a terminal haemorrhagic area on the affected paw.
There were no malformed foetuses at 3 mg/l.
At 1 mg/l there were four malformed foetuses compared to three in the control group. The four malformed foetuses at 1 mg/l involved one showing brachygnathia, one showing retro-oesophageal aortic arch, one showing cardiac ventricular septal defect and one showing brachydactyly and brachymelia of all four limbs. The last mentioned malformation showed apparent similarity to that shown by six foetuses at 9 mg/l. Despite this as similar malformations have occurred spontaneously among control animals in previous studies and in the absence of any other evidence of adverse effects on young at 1 and 3 mg/l, it was considered that overall there was no conclusive indication of a treatment relationship. - Skeletal malformations:
- effects observed, treatment-related
- Description (incidence and severity):
- The incidence of sternebral variants at 9 mg/l was significantly increased (P<0.001). This mainly reflected an increase in the incidence of foetuses with one or more unossified sternebra(e) and was probably associated with the reduced mean foetal weight observed in this group.
At 1 and 3 mg/l marginally higher incidences of sternebral variants in comparison to the control group was neither statistically significant (P>0.05) nor dosage-related.
At 9 mg/l the incidence of foetuses with extra thoraco-lumbar ribs was marginally higher than the control incidence; the difference was not statistically significant (P>0.05).
Incidences at 1 and 3 mg/l were unaffected. - Visceral malformations:
- no effects observed
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects: yes, see above "external malformation".
Effect levels (fetuses)
- Key result
- Dose descriptor:
- NOAEC
- Effect level:
- 3.1 mg/L air (analytical)
- Basis for effect level:
- other: teratogenicity
Overall developmental toxicity
- Key result
- Developmental effects observed:
- yes
- Lowest effective dose / conc.:
- 9 mg/L air (analytical)
- Treatment related:
- yes
- Relation to maternal toxicity:
- developmental effects occurring together with maternal toxicity effects, but not as a secondary non-specific consequence of maternal toxicity effects
Any other information on results incl. tables
Rats inhaled analyzed o-chlorotoluene concentrations of 0, 1, 3, or 9 mg/l for 6 hours/day from days 6 to 19 of pregnancy. Animals in the 3 mg/l group exhibited slight ataxia during exposure. Animals in the 9 mg/l group displayed ataxia, lacrimation and/or salivation as well as a brownish discoloration of the fur. Beginning at 3 mg/l, a dose-dependent reduction in feed intake and body weight gain was observed, as well as a dose-dependent increase in drinking water consumption. No treatment-related effects were seen for animals in the 1 mg/l group. The offspring of the 1 and 3 mg/l groups did not exhibit treatment-related effects. In the 9 mg/l group, a reduction in fetal and litter weights was observed. The incidence of fetal malformations was increased by 6 fetuses (distributed among 4 litters), which each exhibited brachdactylia on one of its fore or hind paws. 5 of these 6 fetuses simultaneously displayed terminal hemorrhaging in the affected paw. In correlation to the reduced mean fetal weight, delayed ossification led to an increased occurrence of skeletal variations. The incidence of visceral anomalies was unchanged, however.
Applicant's summary and conclusion
- Conclusions:
- Under the conditions of the test, a NOAEL of 1.1. mg/L for maternal toxicity (based on reduced feed intake and body weight gain, and general toxicity in the mid and high dose group) and a NOAEL of 3.1 mg/l for developmental toxicity (teratogenicity) was established.
- Executive summary:
On each of gestation days 6 to 19, 25 Charles River rats were transferred to exposure chambers and exposed to a an atmosphere of the test material at concentrations of 0, 1, 3, or 9 mg/l air for 6 hours (analytical concentrations were measured to be 0, 1.1, 1.3, 9.0 mg/l). All animals were killed on day 20 of gestation, dissected and examined for abnormalities and changes in maternal organs. The ovaries and uteri were examined to determine number of corpora lutea, number of resorptions, distribution of live young, number and ditribution of embryonic/foetal deaths, individual foetal weight and gross foetal abnormalities. Half of the pups in each litter were preserved for subsequent sectioning to discover visceral abnormalities; the remainder were fixed for skeletal examination.
Animals in the 3.1 mg/l group exhibited slight ataxia during exposure. Animals in the 9 mg/l group displayed ataxia, lacrimation and/or salivation as well as a brownish discoloration of the fur. Beginning at 3.1 mg/l, a dose-dependent reduction in feed intake and body weight gain was observed, as well as a dose-dependent increase in drinking water consumption. No treatment-related effects were seen for animals in the 1.1 mg/l group. The offspring of the 1.1 and 3.1 mg/l groups did not exhibit treatment-related effects. In the 9 mg/l group, a reduction in fetal and litter weights was observed. The incidence of fetal malformations was increased by 6 fetuses (distributed among 4 litters), which each exhibited brachydactyly on one of its fore or hind paws. Five of these 6 fetuses simultaneously displayed terminal hemorrhaging in the affected paw. Incorrelation to the reduced mean fetal weight, delayed ossification led to an increased occurence of skeletal variations. The incidence of visceral anomalies was unchanged.
The NOAEC for maternal toxicity is 1.1 mg/l, the NOAEC for teratogenicity is 3.1 mg/l.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.